Dysregulation of calcium metabolism in type 1 myotonic dystrophy
- PMID: 30963668
- DOI: 10.1111/imj.14307
Dysregulation of calcium metabolism in type 1 myotonic dystrophy
Abstract
Background: Patients with type 1 myotonic dystrophy (DM1) have a higher incidence of hypercalcaemia compared with the general population. The nature and effects of dysregulated calcium metabolism underpinning this phenomenon have not been fully characterised.
Aims: To determine the characteristics of dysregulated calcium metabolism in patients with DM1 and its association with bone mineral density.
Methods: A retrospective review of medical records of patients with DM1 attending a DM clinic at Logan Hospital, Brisbane, Queensland, between 2005 and 2018 and who had concurrent serum assays performed of corrected serum calcium, 25 hydroxyvitamin D, parathyroid hormone (PTH) and phosphate and for whom results were available for estimated glomerular filtration rate, bone mineral densitometry tests and urinary calcium clearance to creatinine clearance ratio (UCCR).
Results: Forty-four patients with DM1 (22 females, 22 males) were reviewed of whom 14 (32%) had elevated corrected serum calcium and inappropriate PTH. Another 10 patients (23%) had raised PTH with normocalcaemia. Eighteen of 19 (94.7%) patients with hypercalcaemia or high PTH level completed 24-h urinary calcium. All had UCCR ≤0.02. Twelve patients had UCCR <0.01. Seven of 44 (16%) had low 25 hydroxy vitamin D. All patients had normal estimated glomerular filtration rate. None was osteoporotic.
Conclusions: One in three patients with DM1 was hypercalcaemic with unsuppressed PTH. Their clinical features and biochemical pictures resemble those of familial hypocalciuric hypercalcaemia (FHH) and raises the possibility that impaired activity of calcium-sensing receptors, due to abnormal splicing of the calcium-sensing receptor messenger RNA in DM1, causes a FHH-like syndrome ('pseudo-FHH of DM1').
Keywords: bone mineral densitometry; calcium-sensing receptors; hypercalcaemia; osteoporosis; type 1 myotonic dystrophy.
© 2019 Royal Australasian College of Physicians.
Similar articles
-
Vitamin D, parathyroid hormone and muscle impairment in myotonic dystrophies.J Neurol Sci. 2013 Aug 15;331(1-2):132-5. doi: 10.1016/j.jns.2013.06.008. Epub 2013 Jun 25. J Neurol Sci. 2013. PMID: 23809192
-
Familial hypocalciuric hypercalcaemia: a review.Curr Opin Endocrinol Diabetes Obes. 2011 Dec;18(6):359-70. doi: 10.1097/MED.0b013e32834c3c7c. Curr Opin Endocrinol Diabetes Obes. 2011. PMID: 21986511 Review.
-
Plasma 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and parathyroid hormone in familial hypocalciuric hypercalcemia and primary hyperparathyroidism.Eur J Endocrinol. 2008 Dec;159(6):719-27. doi: 10.1530/EJE-08-0440. Epub 2008 Sep 11. Eur J Endocrinol. 2008. PMID: 18787045
-
Vitamin D deficiency in myotonic dystrophy type 1.J Neurol. 2013 Sep;260(9):2330-4. doi: 10.1007/s00415-013-6984-1. Epub 2013 Jun 11. J Neurol. 2013. PMID: 23754696
-
Persistent hypercalcemia with similar familial Hypocalciuric hypercalcemia features: a case report and literature review.BMC Endocr Disord. 2021 Nov 4;21(1):220. doi: 10.1186/s12902-021-00881-9. BMC Endocr Disord. 2021. PMID: 34736428 Free PMC article. Review.
Cited by
-
Characterization of Iron Accumulation in Deep Gray Matter in Myotonic Dystrophy Type 1 and 2 Using Quantitative Susceptibility Mapping and R2* Relaxometry: A Magnetic Resonance Imaging Study at 3 Tesla.Front Neurol. 2019 Dec 13;10:1320. doi: 10.3389/fneur.2019.01320. eCollection 2019. Front Neurol. 2019. PMID: 31920940 Free PMC article.
-
A Novel Class of FKBP12 Ligands Rescues Premature Aging Phenotypes Associated with Myotonic Dystrophy Type 1.Cells. 2024 Nov 22;13(23):1939. doi: 10.3390/cells13231939. Cells. 2024. PMID: 39682688 Free PMC article.
-
Treatment of bilateral encrusted ureteral stents, large volume renal stones, and ureteral stricture in a complex pediatric patient: a surgical video and case review.Am J Clin Exp Urol. 2023 Oct 15;11(5):435-442. eCollection 2023. Am J Clin Exp Urol. 2023. PMID: 37941644 Free PMC article.
-
Mitochondrial Dysfunction in Repeat Expansion Diseases.Antioxidants (Basel). 2023 Aug 10;12(8):1593. doi: 10.3390/antiox12081593. Antioxidants (Basel). 2023. PMID: 37627588 Free PMC article. Review.
References
-
- Cho DH, Tapscott SJ. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta 2007; 1772: 195-204.
-
- Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 1992; 69: 385.
-
- Rau F, Laine J, Ramanoudjame L, Ferry A, Arandel L, Delalande O et al. Abnormal splicing switch of DMD's penultimate exon compromises muscle fibre maintenance in myotonic dystrophy. Nat Commun 2015; 6: 7205.
-
- Kuyumcu-Martinez NM, Cooper TA. Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog Mol Subcell Biol 2006; 44: 133-59.
-
- Meola G. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies. Acta Myol 2013; 32: 154-65.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources